Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts

Bispecific antibodies (bsAbs) engaging T cells are emerging as a promising immunotherapeutic tool for the treatment of hematologic malignancies. Because their low molecular mass, bsAbs have short half-lives. To achieve clinical responses, they have to be infused into patients continously, for a long...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Cancer J
Autors principals: Aliperta, R, Cartellieri, M, Feldmann, A, Arndt, C, Koristka, S, Michalk, I, von Bonin, M, Ehninger, A, Bachmann, J, Ehninger, G, Bornhäuser, M, Bachmann, M P
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2015
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4648523/
https://ncbi.nlm.nih.gov/pubmed/26383821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2015.73
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars